✦ LIBER ✦

Ethics and the anti-dementia drugs

✍ Scribed by Julian C Hughes

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 65 KB
Volume: 15
Category: Article
ISSN: 0885-6230
DOI: 10.1002/1099-1166(200006)15:6<538::aid-gps243>3.0.co;2-s

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-dementia drugs

✍ Harry Allen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## New Drugs for Dementia The introduction of new drugs for dementia has posed a number of problems for clinicians and prescribers with regard to their ecacy and how best they should be introduced into practice. The ®rst ®ve contributions of this issue bring together a number of dierent perspective

Aspirin, anti-inflammatory drugs and ris

Aspirin, anti-inflammatory drugs and risk of dementia

✍ A. S. Henderson; A. F. Jorm; H. Christensen; P. A. Jacomb; A. E. Korten 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Objective. To test the hypothesis that aspirin and non-steroidal anti-in¯ammatory drugs (NSAIDs) may prevent dementia or cognitive impairment. Design. A two-wave longitudinal study over 3.6 years. Setting. A community survey of elderly persons living in Canberra, Australia. Participants. There we

Clinical involvement in anti-dementia dr

Clinical involvement in anti-dementia drug trials—why bother?

✍ Candida Graham; Clive Holmes; James Lindesay 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Finally, there must be realism. There will be limits to the funds available for expensive new drugs. Demand will always exceed resource. This realism must extend to our patients. We need to develop the skills to communicate our uncertainties and the dicult choices we face with our patients and the w

Measuring the effects of anti-dementia d

Measuring the effects of anti-dementia drugs in patients with Alzheimer's disease

✍ S. Curran; J. P. Wattis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

A large number of experimental compounds are being developed for the treatment of patients with Alzheimer's disease (AD). As dierent compounds may have dierent eects on CNS function, depending on which neurotransmitters they aect, adequate pro®ling will require the use of several tests. The dicultie

ETHICS OF ‘INFORMED CONSENT’ IN DEMENTIA

ETHICS OF ‘INFORMED CONSENT’ IN DEMENTIA RESEARCH—THE DEBATE CONTINUES

✍ MANOJ R. AGARWAL; JOSE FERRAN; KATHERINE OST; KENNETH C. M. WILSON 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB 👁 2 views

The Law Commission has recently proposed a legal test of capacity to consent to treatment. Consent to treatment in phase three trials in Alzheimer's disease is usually obtained from both the subject and a carer or next of kin. This article examines the relevance of the Law Commission recommendations

New drugs for dementia: a commissioning

New drugs for dementia: a commissioning nightmare?

✍ Roger Johnson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 1 views